Journal Mobile Options
Table of Contents
35, No. 12, 2012
Issue release date: Dezember 2012
Onkologie 2012;35:755–760
(DOI:10.1159/000345115)
Original Article · Originalarbeit

Biliary Tract Cancer: A Survey Regarding the Current Oncological Daily Care Practice in Germany

Sinn M.a · Bischoff S.a · Nehls O.b · Pelzer U.a · von Weizsäcker F.c · Kubicka S.d · Stieler J.M.a · Caca K.e · Riess H.a
aMedizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité – Universitätsmedizin Berlin, bGastroenterologie und Tumormedizin an St. Anna, Stuttgart, cInnere Medizin I, Schlosspark-Klinik, Berlin, dMedizinische Klinik I, Klinikum am Steigenberg Reutlingen, eKlinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Diabetologie und Infektiologie, Klinikum Ludwigsburg, Germany

Abstract

Background: The low incidence and the variable presentation complicate clinical investigations on biliary tract cancer. The results of Valle et al. in 2009 provided, for the first time, an evidence-based palliative treatment for this rare tumor type. So far no data are available in Germany regarding the current daily care practice. Methods: We started this national survey in May 2011, including about 3,400 members of the AIO (Working Group Medical Oncology), DGHO (German Society of Hematology and Oncology) and GGHBB (Society of Gastroenterology and Hepatology in Berlin and Brandenburg). The standardized online form contained questions concerning field of action and diagnostic and therapeutic procedures. Evaluation was conducted anonymously. Results: 162 responses could be obtained, corresponding to a response rate of about 5%. 70.4% of the respondents were physicians in hospitals, 23.5% stated to work in private practices. 61.7% of the respondents were medical oncologists and 27.2% gastroenterologists. 52.5% of the participants pointed out to use the standard regimen of gemcitabine and cisplatin. For second-line regimen, the most frequent answer (29%) specified the administration of oxaliplatin in combination with 5-fluorouracil (5-FU) or capecitabine. Conclusions: This survey may help to clarify the current oncologic daily care procedures for patients with biliary tract cancer in Germany. The results can be helpful for further clinical investigations or the implementation of a tumor-specific register.

 goto top of outline Author Contacts

Dr. med. Marianne Sinn
Charité – Universitätsmedizin Berlin, Medizinische Klinik
mit Schwerpunkt Hämatologie und Onkologie
Campus Virchow Klinikum
Augustenburger Platz 1, 13353 Berlin, Germany
marianne.sinn@charite.de


 goto top of outline Article Information

Published online: November 20, 2012
Number of Print Pages : 6


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 35, No. 12, Year 2012 (Cover Date: Dezember 2012)

Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.